| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5c564991ae13d25b7772e76de8d0160e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-72
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-02 |
| filingDate |
2007-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_84c8eb5a96dd7c87581d9500fe4ae66c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4d192e80866dca292ea9ecec65465b48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_919168c3977c920e0ef4a96e5db084cf |
| publicationDate |
2009-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2009191211-A1 |
| titleOfInvention |
METHODS FOR DAMAGING CELLS USING EFFECTOR FUNCTIONS OF ANTI-EphA4 ANTIBODIES |
| abstract |
The present invention relates to the use of cytoxicity based on the effector function of anti-EphA4 antibodies. Specifically, the present invention provides methods and pharmaceutical compositions that comprise an anti-EphA4 antibody as an active ingredient for damaging EphA4-expressing cells using antibody effector function. Since EphA4 is strongly expressed in pancreatic cancer cells, the present invention is particularly useful in pancreatic cancer therapies. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8759481-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8383590-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016019280-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9067973-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10428140-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8623829-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016176562-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3473271-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11136400-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10947313-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9284349-B2 |
| priorityDate |
2006-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |